COMPANY ANNOUNCEMENT - No. 1-2021-
BIRKERØD,
suPARnostic® POC+ is co-developed with Austrian-based
As previously announced, the product launch was expected in Q1, 2021. The product launch is now expected in the second half of 2021, following a clinical validation study in Q2, 2021, and an expected CE-IVD approval.
The reason for the delay is related to QC/QA specification development that has been delayed as a result of the COVID-19 pandemic in
This announcement does not affect the strategic objectives of
We remain excited about the suPARnostic® POC+ product and the opportunity it will have in the acute care, pre-hospital, and patient transportation segments of the market and further on potential screening of healthy individuals to assess general inflammatory status.”
The announcement can be found at https://www.virogates.com/investor/announcements
For further information, please contact:
CEO,
Tel. (+45) 2226 1355, email: jk@virogates.com
Certified Advisor:
Västra Hamnen Corporate Finance
Per Lönn
Tel. (+46) 40 200 250, email: per.lonn@vhcorp.se
About
The company was founded in 2000 based on the discovery that suPAR was predictive of outcome in HIV-infections and subsequently in many other disease areas. Headquartered in
ViroGates’ shares (VIRO) are listed on Nasdaq First North Growth Market Denmark. For more information, please visit www.virogates.com.
About suPAR and suPARnostic®
suPAR is the biomarker measured by ViroGates’ suPARnostic® products and is a protein in plasma, measurable in every human being. suPAR is considered a general risk status biomarker indicating disease presence, disease severity and progression, organ damage and mortality risk across disease areas such as cardiovascular diseases, kidney diseases, type 2 diabetes, cancer, etc. Strong scientific evidence from more than 600 clinical trials and studies show that the higher the level of suPAR, the worse the prognosis for the patient.
The suPARnostic® products can be used to support healthcare professionals in making clinical decisions on hospitalization or discharge of acute care patients. The increasing demands on health systems globally and tightening healthcare budgets necessitate efficiency improvements and innovative solutions in hospitals. The use of suPAR in clinical routine in emergency departments can improve patient care and reduce healthcare costs by increasing the number of discharges by 34% and reducing the average hospital length-of-stay by 6% without affecting mortality. suPARnostic® TurbiLatex is currently available on Roche Diagnostics’ cobas, instruments, Siemens ADVIA XPT instruments and the Abbott Labs Architect instruments.
Disclaimer
Prospects about the future reflect
Contacts
Jakob Knudsen , CEO, +45 2226 1355, jk@virogates.com
Attachments
- 20210107-
ViroGates Company announcement 1.pdf
© Ritzau Denmark, source